PainReform (NASDAQ:PRFX) versus ABVC BioPharma (NASDAQ:ABVC) Critical Survey

ABVC BioPharma (NASDAQ:ABVC) and PainReform (NASDAQ:PRFX) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their valuation, analyst recommendations, earnings, risk, dividends, profitability and institutional ownership.

Analyst Recommendations

This is a summary of current recommendations and price targets for ABVC BioPharma and PainReform, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ABVC BioPharma	1	0	0	0	1.00
PainReform	1	0	0	0	1.00

Institutional & Insider Ownership

11.4% of ABVC BioPharma shares are held by institutional investors. Comparatively, 37.3% of PainReform shares are held by institutional investors. 19.0% of ABVC BioPharma shares are held by company insiders. Comparatively, 34.4% of PainReform shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Risk and Volatility

ABVC BioPharma has a beta of 0.61, meaning that its stock price is 39% less volatile than the S&P 500. Comparatively, PainReform has a beta of 1.05, meaning that its stock price is 5% more volatile than the S&P 500.

Profitability

This table compares ABVC BioPharma and PainReform’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
ABVC BioPharma	N/A	-47.68%	-30.97%
PainReform	N/A	N/A	N/A

Earnings & Valuation

This table compares ABVC BioPharma and PainReform”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ABVC BioPharma	$510,000.00	60.62	-$7.91 million	($0.30)	-3.87
PainReform	$20,000.00	40.48	-$5.02 million	($736.66)	-0.00

PainReform has lower revenue, but higher earnings than ABVC BioPharma. ABVC BioPharma is trading at a lower price-to-earnings ratio than PainReform, indicating that it is currently the more affordable of the two stocks.

Summary

PainReform beats ABVC BioPharma on 7 of the 10 factors compared between the two stocks.

About ABVC BioPharma

ABVC BioPharma, Inc., a clinical stage biopharmaceutical company, develops drugs and medical devices to fulfill unmet medical needs in the United States. The company is developing ABV-1501, which is in Phase II clinical trials a combination therapy for triple negative breast cancer; ABV-1504 has completed Phase II clinical trials for major depressive disorders; ABV-1505, which is in Phase II clinical trials for adult attention deficit hyperactivity disorder; ABV-1703, which is in Phase II clinical trials for the treatment of metastatic pancreatic cancer; ABV-1702, which is in Phase II clinical trials to treat myelodysplastic syndromes; and ABV-1601 that is in Phase I/II clinical trials for treating depression in cancer patients. It is also developing ABV-1701 Vitargus that is in Phase II clinical trials for the treatment of retinal detachment or vitreous hemorrhage; and ABV-1519, which is in Phase I/II clinical trials for the treatment of non-small cell lung cancer. ABVC BioPharma, Inc. has a co-development agreement with Rgene Corporation; and collaboration agreements with BioHopeKing Corporation and BioFirst Corporation. The company is based in Fremont, California. ABVC BioPharma, Inc. operates as a subsidiary of YuanGene Corporation.

About PainReform

PainReform Ltd., a clinical stage specialty pharmaceutical company, focuses on the reformulation of established therapeutics and provides an extended period of post-surgical pain relief in Israel. It develops PRF-110, a viscous clear oil-based solution that is instilled directly into the surgical wound to provide localized and extended post-operative analgesia, as well as in Phase 3 clinical trial for pain treatment of patients undergoing bunionectomy and second trial for pain treatment of hernia repair operations. The company was incorporated in 2007 and is based in Tel Aviv, Israel.